Cancer genome profiling of prostate cancer identifies a patient with a novel EFNA1-NTRK1 fusion gene.

IF 0.5 Q4 ONCOLOGY

International Cancer Conference Journal Pub Date : 2025-05-09 eCollection Date: 2025-07-01 DOI:10.1007/s13691-025-00769-8

Tomohiro Kanaki, Koji Hatano, Shinichiro Tahara, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Tsuyoshi Takada, Norio Nonomura

{"title":"Cancer genome profiling of prostate cancer identifies a patient with a novel EFNA1-NTRK1 fusion gene.","authors":"Tomohiro Kanaki, Koji Hatano, Shinichiro Tahara, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Tsuyoshi Takada, Norio Nonomura","doi":"10.1007/s13691-025-00769-8","DOIUrl":null,"url":null,"abstract":"NTRK gene fusions serve as oncogenic drivers in solid tumors. While these fusions are uncommon in prostate cancer, they can be detected through cancer genome profiling tests. In a study of 68 prostate cancer cases analyzed with comprehensive cancer genome profiling, we identified a single instance of a novel EFNA1-NTRK1 fusion. The patient, a 56-year-old male diagnosed with prostate cancer and bone metastasis, presented with an initial PSA level of 323 ng/mL, a Gleason score of 4 + 4, and was classified as cT3bN0M1b. He underwent combined androgen blockade therapy but progressed to castration-resistant prostate cancer after 31 months. Despite previous treatments with androgen receptor signaling inhibitors and chemotherapies, the cancer continued to advance. Following the identification of an EFNA1-NTRK1 gene fusion via a cancer genome profiling test, the patient received treatment with larotrectinib. Although the initial biopsy showed positive pan-TRK staining in the prostate cancer tissue, the response to larotrectinib was limited in this case.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"296-301"},"PeriodicalIF":0.5000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229356/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-025-00769-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

NTRK gene fusions serve as oncogenic drivers in solid tumors. While these fusions are uncommon in prostate cancer, they can be detected through cancer genome profiling tests. In a study of 68 prostate cancer cases analyzed with comprehensive cancer genome profiling, we identified a single instance of a novel EFNA1-NTRK1 fusion. The patient, a 56-year-old male diagnosed with prostate cancer and bone metastasis, presented with an initial PSA level of 323 ng/mL, a Gleason score of 4 + 4, and was classified as cT3bN0M1b. He underwent combined androgen blockade therapy but progressed to castration-resistant prostate cancer after 31 months. Despite previous treatments with androgen receptor signaling inhibitors and chemotherapies, the cancer continued to advance. Following the identification of an EFNA1-NTRK1 gene fusion via a cancer genome profiling test, the patient received treatment with larotrectinib. Although the initial biopsy showed positive pan-TRK staining in the prostate cancer tissue, the response to larotrectinib was limited in this case.

查看原文本刊更多论文

前列腺癌的癌症基因组分析鉴定了一个新的EFNA1-NTRK1融合基因的患者。

NTRK基因融合在实体瘤中起致癌驱动作用。虽然这些融合在前列腺癌中并不常见，但它们可以通过癌症基因组分析测试检测到。在一项对68例前列腺癌病例进行综合癌症基因组分析的研究中，我们发现了一个新的EFNA1-NTRK1融合的实例。患者，56岁男性，诊断为前列腺癌及骨转移，初始PSA水平323 ng/mL， Gleason评分4 + 4，分类为cT3bN0M1b。他接受了联合雄激素阻断治疗，但在31个月后发展为去势抵抗性前列腺癌。尽管先前使用雄激素受体信号抑制剂和化疗治疗，但癌症仍在继续发展。在通过癌症基因组分析测试鉴定EFNA1-NTRK1基因融合后，患者接受了larorectinib治疗。虽然最初的活检显示前列腺癌组织泛trk染色阳性，但在本病例中对larorectinib的反应有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)